Generic Name and Formulations:
Mitotane 500mg; scored tabs.
Indications for LYSODREN:
Inoperable adrenal cortical carcinoma.
2–6g/day in divided doses (3–4 times/day). Doses may be increased incrementally to achieve a blood concentration of 14–20mg/L, or as tolerated. Dose modifications: see full labeling.
Discontinue temporarily following shock or severe trauma. CNS toxicity (esp. with high doses). Adrenal insufficiency: give steroid replacement as clinically indicated; measure free cortisol and ACTH levels. Ovarian macrocysts in premenopausal women. Hepatic impairment. Pregnancy; avoid. Use effective contraception during and after discontinuation until mitotane levels are undetectable. Nursing mothers: not recommended.
Adrenal cytotoxic agent.
Concomitant oral anticoagulants, CYP3A4 substrates; monitor for change in dose requirements.
Anorexia, nausea, vomiting, diarrhea, depression, dizziness, vertigo, rash, neutropenia, growth retardation, hypothyroidism, confusion, headache, ataxia, mental impairment, weakness, dysarthria, maculopathy, hepatitis, elevated liver enzymes, gynecomastia, hypercholesterolemia, hypertriglyceridemia.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- RET Inhibitor Gets Breakthrough Treatment Status for Medullary Thyroid Cancer
- Physical Activity as a Lifestyle Factor Influencing Early Menopause
- Situation Framing, Language Can Influence Decision-Making
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Oral Contraceptives Associated With Ventricular Repolarization Alterations